Key Highlights
- Adial Pharmaceuticals completed its Azora Therapeutics acquisition.
- The company is shifting focus to AT177, an oral colon-targeted AhR agonist for ulcerative colitis.
- Adial closed the first $32 million Tranche of up to $64 million in financing.
- Q2 cash rose to $28.7 million, with runway into the second half of 2027.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) completed its Acquisition of Azora Therapeutics, shifting focus to AT177, an oral colon-targeted AhR agonist for ulcerative colitis, while closing the first $32 million tranche of up to $64 million in financing.
What Happened
Q2 cash rose to $28.7 million, with runway extending into the second half of 2027, though net loss widened to $52.0 million, mainly from a non-cash $46.2 million acquired in-process Research and Development charge tied to the acquisition.
Market Reaction
The disclosed information does not include stock price or trading data for Adial Pharmaceuticals following the completed acquisition.
Outlook
Continued clinical advancement of AT177 in ulcerative colitis, supported by the extended cash runway into the second half of 2027, is likely to remain the key Factor shaping sentiment toward Adial Pharmaceuticals' stock going forward.
FAQs
Q: What acquisition did Adial Pharmaceuticals complete?
A: The acquisition of Azora Therapeutics, shifting the company's focus to AT177 for ulcerative colitis.
Q: Why did Adial's net loss widen to $52.0 million?
A: Mainly due to a non-cash $46.2 million acquired IPR&D charge tied to the Azora Therapeutics acquisition.
Q: How long is Adial's cash runway expected to last?
A: Into the second half of 2027, with Q2 cash of $28.7 million and the first $32 million tranche of up to $64 million in financing closed.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.